Clinicolaboratory Predictors of Outcome in Children With Encephalitis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorAssiut University

About this trial

. A glycolytic enzyme called enolase is primarily found in neurons. A dimeric isoform of enolase called neuron-specific enolase (NSE) exists. It can be found in neurons, platelets, erythrocytes, and other neuroectodermal cells.It is one of the laboratory biomarkers that could be investigated in cases of encephalopathy, which can be found in both blood and cerebrospinal fluid, might be a helpful biomarker for determining brain injury prognosis and neuronal damage.(4) High S-100beta levels were associated with higher intensive care unit mortality and represented the strongest independent predictor of intensive care unit survival, whereas neuron-specific enolase (NSE) and the Glasgow Coma Scale failed to predict fatal outcome.(5) (NSE) and S100B are important as a diagnostic and a prognostic value in pediatric encephalopathy which is common and is potentially life threatening, previous studies were done worldwide to detect its diagnostic and prognostic value in acute encephalopathy among adult and pediatric age groups.(4) ,so we asses (NSE) and S100B to detect the the out come of acute encephalopathy

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Pediatric population aged 1month to 18 years.

Decreased level of consciousness, personality change, or psychiatric manifestations lasting >24 h (in toddlers and infants, may present as increased irritability or lethargy)

No alternative diagnosis to explain presentation

Seizure (new onset)

Disqualifiers

1. Neonates and adults ( <1 month or >18 years) 2. If they had a diagnosis of delirium or encephalopathy secondary to sepsis, toxins,renal ,hepatic or metabolic causes (hypoglycemia, electrolyte disturbances

Trial population

1\. Pediatric population aged 1month to 18 years. * Decreased level of consciousness, personality change, or psychiatric manifestations lasting \>24 h (in toddlers and infants, may present as increased irritability or lethargy) * No alternative diagnosis to explain presentation * Seizure (new onset) * Fever (≥38.0°C) * Focal neurologic findings (new onset) * CSF WBC ≥5/mm3 * Acute abnormality on brain MRI

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • CSF analysis and culture including S100B,Neuron Specific Enolase(NSE)

    Diagnostic test

    CSF analysis and culture including S100B,Neuron Specific Enolase(NSE)

Treatment groups

90 Participants
are divided into 1 treatment group
Group A: Children with encephalitis1 intervention

Trial outcomes

Primary outcomes

1

To asses clinical ,radiological laboratory biomarkers ( CSF Neuron-Specific Enolase and S100B )as outcome predictors of encephalitis

To asses clinical ,radiological laboratory biomarkers ( CSF Neuron-Specific Enolase and S100B )as outcome predictors of encephalitis

Time frame
1 month

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: